FENC vs. MGTX, VALN, IMTX, VECT, SANA, RLAY, OPT, MAZE, CGEM, and AUTL
Should you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include MeiraGTx (MGTX), Valneva (VALN), Immatics (IMTX), VectivBio (VECT), Sana Biotechnology (SANA), Relay Therapeutics (RLAY), Opthea (OPT), Maze Therapeutics (MAZE), Cullinan Therapeutics (CGEM), and Autolus Therapeutics (AUTL). These companies are all part of the "biological products, except diagnostic" industry.
Fennec Pharmaceuticals vs.
MeiraGTx (NASDAQ:MGTX) and Fennec Pharmaceuticals (NASDAQ:FENC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation, earnings and community ranking.
MeiraGTx has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500.
In the previous week, MeiraGTx had 11 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 14 mentions for MeiraGTx and 3 mentions for Fennec Pharmaceuticals. Fennec Pharmaceuticals' average media sentiment score of 1.57 beat MeiraGTx's score of 1.19 indicating that Fennec Pharmaceuticals is being referred to more favorably in the news media.
MeiraGTx presently has a consensus target price of $24.50, suggesting a potential upside of 256.57%. Fennec Pharmaceuticals has a consensus target price of $13.67, suggesting a potential upside of 118.84%. Given MeiraGTx's higher probable upside, equities research analysts plainly believe MeiraGTx is more favorable than Fennec Pharmaceuticals.
Fennec Pharmaceuticals received 9 more outperform votes than MeiraGTx when rated by MarketBeat users. However, 71.75% of users gave MeiraGTx an outperform vote while only 66.67% of users gave Fennec Pharmaceuticals an outperform vote.
Fennec Pharmaceuticals has a net margin of -2.30% compared to MeiraGTx's net margin of -633.05%. Fennec Pharmaceuticals' return on equity of -53.38% beat MeiraGTx's return on equity.
Fennec Pharmaceuticals has higher revenue and earnings than MeiraGTx. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.
67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 55.5% of Fennec Pharmaceuticals shares are owned by institutional investors. 8.4% of MeiraGTx shares are owned by company insiders. Comparatively, 11.0% of Fennec Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Fennec Pharmaceuticals beats MeiraGTx on 12 of the 19 factors compared between the two stocks.
Get Fennec Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fennec Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:FENC) was last updated on 3/31/2025 by MarketBeat.com Staff
